Hangzhou Ruiao Biopharmaceutical

Hangzhou Ruiao Biopharmaceutical (Hangzhou Ruiao Biotechnology Co., Ltd.) is an early-stage biotechnology company based in Hangzhou, China, specializing in the development of targeted protein degraders and advanced drug delivery systems. Founded as a spin-off from Westlake University, the company leverages the research of Professor Jianjun Cheng and Dr. Kaimin Cai in the fields of nanomedicine and chemical biology. Its primary focus is on the development of Sos1 protein degraders (PROTACs) for the treatment of RAS-driven cancers. Additionally, the company is developing technologies for metabolic labeling and click chemistry-based targeting to enhance the precision of oncology therapeutics and diagnostics. The company aims to translate cutting-edge academic research into clinical therapies for unmet medical needs in oncology.